InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

InflaRx N.V. IFRX on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) recommended that the trial be stopped due to futility.Pyoderma gangrenosum is a rare, chronic skin condition characterized by painful, necrotic ulcers that often appear on the legs.The recommendation was based on data analysis of the first 30 patients enrolled in the study, with no unexpected adverse events ...